Oxycontin Related Published Studies
Well-designed clinical trials related to Oxycontin (Oxycodone)
Comparison of subjective effects of extended-release versus immediate-release
oxycodone/acetaminophen tablets in healthy nondependent recreational users of
prescription opioids: a randomized trial. [2014]
A randomized, double-blind, placebo-controlled study of oral oxycodone plus
acetaminophen for the treatment of pain in photodynamic therapy on port wine
stains. [2014]
Safety and efficacy of once-daily hydromorphone extended-release versus
twice-daily oxycodone hydrochloride controlled-release in chinese patients with
cancer pain: a phase 3, randomized, double-blind, multicenter study. [2014]
Oral oxycodone plus intravenous acetaminophen versus intravenous morphine sulfate
in acute bone fracture pain control: a double-blind placebo-controlled randomized
clinical trial. [2014]
Bowel function after tapentadol and oxycodone immediate release (IR) treatment in
patients with low back or osteoarthritis pain. [2013]
Diclofenac with or without an antiemetic for acute migraine headaches in adults. [2013]
Comparison of the efficacy and safety of dual-opioid treatment with morphine plus
oxycodone versus oxycodone/acetaminophen for moderate to severe acute pain after
total knee arthroplasty. [2013]
A comparison of oxycodone prolonged-release vs. oxycodone + naloxone
prolonged-release after laparoscopic hysterectomy. [2013]
Effects of the NK1 antagonist, aprepitant, on response to oral and intranasal
oxycodone in prescription opioid abusers. [2013]
Tolerability and efficacy of two synergistic ratios of oral morphine and
oxycodone combinations versus morphine in patients with chronic noncancer pain. [2012]
Liver cancer: effects, safety, and cost-effectiveness of controlled-release
oxycodone for pain control after TACE. [2012]
A randomized, double-blind, active-controlled, double-dummy, parallel-group study
to determine the safety and efficacy of oxycodone/naloxone prolonged-release
tablets in patients with moderate/severe, chronic cancer pain. [2012]
Oxycodone lengthens reproductions of suprasecond time intervals in human research volunteers. [2011.08]
Clinical outcomes during opioid titration following initiation with or conversion to Remoxy(R), an extended-release formulation of oxycodone. [2011.07]
Inhibition of cytochrome P450 3A by clarithromycin uniformly affects the pharmacokinetics and pharmacodynamics of oxycodone in young and elderly volunteers. [2011.06]
Oral oxycodone offers equivalent analgesia to intravenous patient-controlled analgesia after total hip replacement: a randomized, single-centre, non-blinded, non-inferiority study. [2011.06]
Analgesic and adverse effects of a fixed-ratio morphine-oxycodone combination (MoxDuo) in the treatment of postoperative pain. [2011.05]
Efficacy and safety of an extended-release oxycodone (Remoxy) formulation in patients with moderate to severe osteoarthritic pain. [2011.05]
Positive and negative subjective effects of extended-release oxymorphone versus controlled-release oxycodone in recreational opioid users. [2011.05]
Comparable efficacy and superior gastrointestinal tolerability (nausea, vomiting, constipation) of tapentadol compared with oxycodone hydrochloride. [2011.05]
The abuse potential of Remoxy((R)), an extended-release formulation of oxycodone, compared with immediate- and extended-release oxycodone. [2011.04]
Psychopharmacological effects of oxycodone in volunteers with and without generalized anxiety disorder. [2011.04]
Naloxone as part of a prolonged release oxycodone/naloxone combination reduces oxycodone-induced slowing of gastrointestinal transit in healthy volunteers. [2011.04]
The efficacy and safety of fentanyl buccal tablet compared with immediate-release oxycodone for the management of breakthrough pain in opioid-tolerant patients with chronic pain. [2011.03]
Efficacy and safety of oxycodone HCl/niacin tablets for the treatment of moderate-to-severe postoperative pain following bunionectomy surgery. [2011.03]
Miconazole oral gel increases exposure to oral oxycodone by inhibition of CYP2D6 and CYP3A4. [2011.03]
Efficacy of oxycodone/paracetamol for patients with bone-cancer pain: a multicenter, randomized, double-blinded, placebo-controlled trial. [2011.01.05]
The subjective, reinforcing, and analgesic effects of oxycodone in patients with chronic, non-malignant pain who are maintained on sublingual buprenorphine/naloxone. [2011.01]
Effect of the inhibition of CYP3A4 or CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone. [2011.01]
Effect of inhibition of cytochrome P450 enzymes 2D6 and 3A4 on the pharmacokinetics of intravenous oxycodone: a randomized, three-phase, crossover, placebo-controlled study. [2011]
Post hoc analyses of data from a 90-day clinical trial evaluating the
tolerability and efficacy of tapentadol immediate release and oxycodone immediate
release for the relief of moderate to severe pain in elderly and nonelderly
patients. [2011]
Analgesic and adverse effects of a fixed-ratio morphine-oxycodone combination
(MoxDuo) in the treatment of postoperative pain. [2011]
Efficacy and safety of an extended-release oxycodone (Remoxy) formulation in
patients with moderate to severe osteoarthritic pain. [2011]
A pharmacokinetic and pharmacodynamic study of oral oxycodone in a human experimental pain model of hyperalgesia. [2010.12.01]
Reduced cognitive and psychomotor impairment with extended-release oxymorphone versus controlled-release oxycodone. [2010.11]
Morphine versus oxycodone in pancreatic cancer pain: a randomized controlled study. [2010.11]
A comparison of the respiratory effects of oxycodone versus morphine: a randomised, double-blind, placebo-controlled investigation. [2010.10]
Oxycodone concentrations are greatly increased by the concomitant use of ritonavir or lopinavir/ritonavir. [2010.10]
Intravenous oxycodone, hydrocodone, and morphine in recreational opioid users: abuse potential and relative potencies. [2010.10]
Predicting the analgesic effect to oxycodone by 'static' and 'dynamic' quantitative sensory testing in healthy subjects. [2010.10]
Grapefruit juice enhances the exposure to oral oxycodone. [2010.10]
Efficacy and safety of combined prolonged-release oxycodone and naloxone in the management of moderate/severe chronic non-malignant pain: results of a prospectively designed pooled analysis of two randomised, double-blind clinical trials. [2010.09.29]
A double-blind, placebo-controlled study of dual-opioid treatment with the combination of morphine plus oxycodone in patients with acute postoperative pain. [2010.09]
Different effects of morphine and oxycodone in experimentally evoked hyperalgesia: a human translational study. [2010.08]
Human abuse liability assessment of oxycodone combined with ultra-low-dose naltrexone. [2010.07]
Exposure to oral oxycodone is increased by concomitant inhibition of CYP2D6 and 3A4 pathways, but not by inhibition of CYP2D6 alone. [2010.07]
Genetic polymorphisms and drug interactions modulating CYP2D6 and CYP3A activities have a major effect on oxycodone analgesic efficacy and safety. [2010.06]
Evaluation of study discontinuations with tapentadol inmmediate release and oxycodone immediate release in patients with low back or osteoarthritis pain. [2010.05]
A randomized, controlled trial of oxycodone versus placebo in patients with postherpetic neuralgia and painful diabetic neuropathy treated with pregabalin. [2010.05]
Psychopharmacological effects of oxycodone in healthy volunteers: roles of alcohol-drinking status and sex. [2010.03.01]
Dexamethasone decreases oxycodone consumption following osteotomy of the first metatarsal bone: a randomized controlled trial in day surgery. [2010.03]
Oxycodone/acetaminophen at low dosage: an alternative pain treatment for patients with rheumatoid arthritis. [2010.01]
Effect of telithromycin on the pharmacokinetics and pharmacodynamics of oral oxycodone. [2010.01]
A randomised comparison of regular oral oxycodone and intrathecal morphine for post-caesarean analgesia. [2010.01]
Efficacy and safety of Tapentadol extended release compared with oxycodone controlled release for the management of moderate to severe chronic pain related to osteoarthritis of the knee: a randomized, double-blind, placebo- and active-controlled phase III study. [2010]
A double-blind, placebo-controlled study of dual-opioid treatment with the
combination of morphine plus oxycodone in patients with acute postoperative pain. [2010]
Different effects of morphine and oxycodone in experimentally evoked
hyperalgesia: a human translational study. [2010]
Evaluation of study discontinuations with tapentadol inmmediate release and
oxycodone immediate release in patients with low back or osteoarthritis pain. [2010]
Predicting the analgesic effect to oxycodone by 'static' and 'dynamic'
quantitative sensory testing in healthy subjects. [2010]
Human abuse liability assessment of oxycodone combined with ultra-low-dose
naltrexone. [2010]
A randomized, controlled trial of oxycodone versus placebo in patients with
postherpetic neuralgia and painful diabetic neuropathy treated with pregabalin. [2010]
The antinociceptive effect and adverse drug reactions of oxycodone in human
experimental pain in relation to genetic variations in the OPRM1 and ABCB1 genes. [2010]
A randomised comparison of regular oral oxycodone and intrathecal morphine for
post-caesarean analgesia. [2010]
Use of an algorithm applied to urine drug screening to assess adherence to an oxycontin regimen. [2009.11]
The prescription opioid, oxycodone, does not alter behavioral measures of impulsivity in healthy volunteers. [2009.11]
Efficacy of oxycodone/acetaminophen and codeine/acetaminophen vs. conventional therapy in elderly women with persistent, moderate to severe osteoarthritis-related pain. [2009.11]
Dexamethasone decreases oxycodone consumption following osteotomy of the first metatarsal bone: a randomized controlled trial in day surgery. [2009.10.10]
A comparison of intravenous oxycodone and intravenous morphine in patient-controlled postoperative analgesia after laparoscopic hysterectomy. [2009.10]
Analgesic efficacy of peripheral kappa-opioid receptor agonist CR665 compared to oxycodone in a multi-modal, multi-tissue experimental human pain model: selective effect on visceral pain. [2009.09]
Relationship between rate of infusion and reinforcing strength of oxycodone in humans. [2009.07]
Rifampin greatly reduces the plasma concentrations of intravenous and oral oxycodone. [2009.06]
A randomized, double-blind, placebo-controlled phase 3 study of the relative efficacy and tolerability of tapentadol IR and oxycodone IR for acute pain. [2009.06]
Within-subject comparison of the psychopharmacological profiles of oral hydrocodone and oxycodone combination products in non-drug-abusing volunteers. [2009.04.01]
The hypoalgesic effect of oxycodone in human experimental pain models in relation to the CYP2D6 oxidation polymorphism. [2009.04]
A randomized, placebo-controlled trial of oxycodone and of gabapentin for acute pain in herpes zoster. [2009.04]
Combined prolonged-release oxycodone and naloxone improves bowel function in patients receiving opioids for moderate-to-severe non-malignant chronic pain: a randomised controlled trial. [2009.03]
Voriconazole drastically increases exposure to oral oxycodone. [2009.03]
A randomized, double-blind, phase III study comparing multiple doses of tapentadol IR, oxycodone IR, and placebo for postoperative (bunionectomy) pain. [2009.03]
A randomized, double-blind, phase III study comparing multiple doses of tapentadol IR, oxycodone IR, and placebo for postoperative (bunionectomy) pain * [2009.02.10]
A randomized, placebo-controlled trial of oxycodone and of gabapentin for acute pain in herpes zoster. [2009.02.03]
Efficacy and tolerability of tapentadol immediate release and oxycodone HCl immediate release in patients awaiting primary joint replacement surgery for end-stage joint disease: a 10-day, phase III, randomized, double-blind, active- and placebo-controlled study. [2009.02]
Effect of delayed activated charcoal on acetaminophen concentration after simulated overdose of oxycodone and acetaminophen. [2009.02]
A randomised controlled trial with prolonged-release oral oxycodone and naloxone to prevent and reverse opioid-induced constipation. [2009.01]
Controlled-release oxycodone and pregabalin in the treatment of neuropathic pain: results of a multicenter Italian study. [2009]
Clinical equivalence of controlled-release oxycodone 20 mg and controlled-release tramadol 200 mg after surgery for breast cancer. [2009]
Analgesic efficacy and safety of oxycodone in combination with naloxone as prolonged release tablets in patients with moderate to severe chronic pain. [2008.12]
Oxycodone versus codeine for triage pain in children with suspected forearm fracture: a randomized controlled trial. [2008.09]
Pharmacokinetic-pharmacodynamic modeling of morphine and oxycodone concentrations and analgesic effect in a multimodal experimental pain model. [2008.05]
The effect of single-dose tramadol on oxycodone clearance. [2007.11]
Postoperative intravenous morphine consumption, pain scores, and side effects with perioperative oral controlled-release oxycodone after lumbar discectomy. [2007.07]
Efficacy and tolerability of once-daily OROS hydromorphone and twice-daily extended-release oxycodone in patients with chronic, moderate to severe osteoarthritis pain: results of a 6-week, randomized, open-label, noninferiority analysis. [2007.05]
PTI-821: sustained-release oxycodone using gel-cap technology. [2007.03]
A randomized, open-label, multicenter trial comparing once-a-day AVINZA (morphine sulfate extended-release capsules) versus twice-a-day OxyContin (oxycodone hydrochloride controlled-release tablets) for the treatment of chronic, moderate to severe low back pain: improved physical functioning in the ACTION trial. [2007.01]
A randomized, open-label study of once-a-day AVINZA (morphine sulfate extended-release capsules) versus twice-a-day OxyContin (oxycodone hydrochloride controlled-release tablets) for chronic low back pain: the extension phase of the ACTION trial. [2006.11]
Randomized trial comparing polymer-coated extended-release morphine sulfate to controlled-release oxycodone HCl in moderate to severe nonmalignant pain. [2006.08]
A comparative study of oxycodone and morphine in a multi-modal, tissue-differentiated experimental pain model. [2006.07]
Effects of an opioid (oxycodone/paracetamol) and an NSAID (bromfenac) on driving ability, memory functioning, psychomotor performance, pupil size, and mood. [2006.06]
The ACTION study: a randomized, open-label, multicenter trial comparing once-a-day extended-release morphine sulfate capsules (AVINZA) to twice-a-day controlled-release oxycodone hydrochloride tablets (OxyContin) for the treatment of chronic, moderate to severe low back pain. [2006.05]
Economic evaluation of controlled-release oxycodone vs oxycodone-acetaminophen for osteoarthritis pain of the hip or knee. [2006.04]
Treatment of persistent pain associated with osteoarthritis with controlled-release oxycodone tablets in a randomized controlled clinical trial. [2005.11]
Impact of controlled-release oxycodone on efficacy beliefs and coping efforts among osteoarthritis patients with moderate to severe pain. [2005.11]
|